3975-51-7

Upstream product

• 50727-06-5 5-hydroxy-isoindole-1,3-dione 
• 108-91-8 cyclohexylamine 
• 27550-59-0 4-hydroxyphthalic anhydride 
• 4998-76-9 cyclohexylamine hydrochloride 
• 610-35-5 4-hydroxyphthalic acid 

Downstream Products

• 109803-89-6 4-(2-Cyclohexyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yloxy)-butyric acid ethyl ester 
• 1242154-45-5 2-cyclohexylisoindole-1,3-dion-5-yl (E)-3-(4-nitrophenyl)acrylate 
• 1260225-04-4 C₂₉H₂₈ClNO₄ 
• 1260224-93-8 4-chloro-3'-((2-cyclohexyl-1-oxoisoindolin-5-yloxy)methyl)biphenyl-3-carboxylic acid 
• 153144-28-6 2-cyclohexyl-5-hydroxyisoindolin-1-one 
• 109804-21-9 4-(2-Cyclohexyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yloxy)-butyric acid 
• 109804-22-0 (2-Cyclohexyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yloxy)-acetic acid 
• 109803-90-9 (2-Cyclohexyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yloxy)-acetic acid ethyl ester 

Relevant academic research and scientific papers

Efficient conversion of acids and esters to amides and transamidation of primary amides using OSU-6

OSU-6, an MCM-41 type hexagonal mesoporous silica with strong Bronsted acid properties, has been used to promote the high-yield conversion of carboxylic acids and esters to carboxamides as well as transamidations of primary amides in a one-pot solventless approach. A metal-free heterogeneous catalyst that promotes all of these processes has not been previously reported. OSU-6 enables these transformations to proceed in shorter times and at lower temperatures for a broad range of substrates. An added benefit is that the catalyst can be recycled and reused multiple times without significant loss of activity.

Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats

The modification of 3′-((2-cyclopentyl-6,7-dimethyl-1-oxo-2,3- dihydro-1H-inden-5-yloxy)methyl)biphenyl-4-carboxylic acid (BINA, 1) by incorporating heteroatoms into the structure and replacing the cyclopentyl moiety led to the development of new mGluR2 positive allosteric modulators (PAMs) with optimized potency and superior druglike properties. These analogues are more potent than 1 in vitro and are highly selective for mGluR2 vs other mGluR subtypes. They have significantly improved pharmacokinetic (PK) properties, with excellent oral bioavailability and brain penetration. The benzisothiazol-3-one derivative 14 decreased cocaine self-administration in rats, providing proof-of-concept for the use of mGluR2 PAMs for the treatment of cocaine dependence.

Development of tryptase inhibitors derived from thalidomide

A novel series of tryptase inhibitors with a N-phenylphthalimide skeleton structurally derived from thalidomide (1) has been developed. Structure-activity relationship studies led to a potent and selective tryptase inhibitor, 2-(4-cyanophenyl)isoindole-1,3-dione-5-yl 3-(2-aminopyridin-5-yl)propanoate (7), with the IC50 value of 78 nM.